Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 5/20 | 0.84 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.84 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893298 | 0.94 | KCNK3 (0.75) | KCNK3KCNK9MEN1KMT2ALMNA | |
| SCHEMBL5504642 | 0.86 | MEN1 (0.83) | KCNK3KCNK9MEN1KMT2ANPSR1 | |
| SCHEMBL16941524 | 0.85 | MEN1 (0.69) | KCNK3KCNK9MEN1KMT2ALMNA | |
| SCHEMBL15528334 | 0.81 | RXFP1 (0.74) | KCNK3KCNK9MEN1KMT2AMAPT | |
| SCHEMBL14372370 | 0.81 | SMN1; SMN2 (0.74) | KCNK3KCNK9LMNARXFP1ALDH1A1 | |
| SCHEMBL20404617 | 0.80 | MAPT (0.62) | KCNK3KCNK9MEN1KMT2ALMNA | |
| SCHEMBL4432149 | 0.79 | RAB9A (0.84) | KCNK3KCNK9MEN1KMT2ALMNA | |
| SCHEMBL4428095 | 0.79 | MEN1 (0.77) | KCNK3KCNK9MEN1KMT2ALMNA | |
| SCHEMBL15530659 | 0.78 | RXFP1 (1.00) | KCNK3KCNK9MAPTRXFP1 | |
| SCHEMBL18893166 | 0.78 | RXFP1 (0.80) | KCNK3KCNK9MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-20130310351-A1 | Treating Long QT Syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012054718-A2 | TREATING LONG QT SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310351-A1 | Treating Long QT Syndrome | TNNI3, TNNT2, TNNC1 | KCNK3 300/4885KCNK9 346/4885MEN1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.